Silence Therapeutics PLC (NAS:SLN)
$ 22.33 1.19 (5.63%) Market Cap: 1.04 Bil Enterprise Value: 973.87 Mil PE Ratio: 0 PB Ratio: 41.35 GF Score: 43/100

Silence Therapeutics PLC at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 17, 2020 / 04:30PM GMT
Release Date Price: $18.5
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Good afternoon, and welcome once again to the Morgan Stanley 18th Annual Global Healthcare Conference. I'm one of the biotech analysts here. My name is David Lebowitz. Before we get going, let me just go through the requisite disclosures. Please note that this webcast is for Morgan Stanley's clients and Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

And with that, I'm happy to welcome into our next session from Silence Therapeutics, CFO, Rob Quinn; and CMO, Giles Campion. Silence is a development stage siRNA company, developing drugs for a wide variety of different types of diseases.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot